Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506455 | 0.88 | PPARG (0.61) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL7078432 | 0.88 | MRGPRX4 (0.46) | MRGPRX4CFDALDH1A1KDM4ELDHA | |
| SCHEMBL6866159 | 0.87 | CFD (0.70) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL31119031 | 0.86 | HPGD (0.54) | MRGPRX4ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL1287529 | 0.86 | HPGD (0.54) | MRGPRX4ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL12837926 | 0.86 | MRGPRX4 (0.57) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL384685 | 0.86 | MRGPRX4 (0.57) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL5453077 | 0.84 | MRGPRX4 (0.59) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL31252031 | 0.84 | MRGPRX4 (0.59) | MRGPRX4CFDALDH1A1KDM4EHPGD | |
| SCHEMBL20522149 | 0.83 | PPARG (0.60) | MRGPRX4CFDALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023077040-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| EP-3303415-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | Novartis AG (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193912-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC. (CH) | 2016-12-08 | — | — | US | disclosed |
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1000038-B1 | NOVEL PYRIMIDIN DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| US-6200981-B1 | FOR TREATING INFLAMMATORY DISEASES SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS, RHEUMATOID ARTHRITIS, MYOCARDIAL ISCHAEMIA, CYSTIC FIBROSIS, ARTHEREOSCLEROSIS, RESTENOSIS, PERIDONTAL DISEASE, SEPTIC SHOCK, OSTEOARTHRITIS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1000038-A1 | NOVEL PYRIMIDIN DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005123-A1 | NOVEL PYRIMIDIN DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | MRGPRX4 4778/4885CFD 1765/4885ALDH1A1 1953/4885 |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | MRGPRX4 821/4885CFD 3531/4885ALDH1A1 2023/4885 |
| US-20160357031-A1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | SIRT5, IK, IGLV6-57 | MRGPRX4 4778/4885CFD 1765/4885ALDH1A1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.